ZETAPRIME
Live / Applied — First extension granted (statement of use) (as of 27 Mar 2026)
What this means for you
Not registered yet, but its 22 Jan 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99014675
- Mark type
- Stylized text
- Filed
- 22 Jan 2025
- Published for opposition
- 04 Nov 2025
- Attorney of record
- Katherine P. Califa
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of tumors and metastatic tumors; Pharmaceutical preparations for destroying, inhibiting or preventing the spread of uncontrolled growth of abnormal tissues in the nature of tumors and metastatic tumors.
Owner
- Zetagen Therapeutics, Inc., Syracuse, NY, US
- Zetagen Therapeutics, Inc., Syracuse, NY, US
Prosecution history
- 28 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Mar 2026 — SOU EXTENSION 1 GRANTED
- 27 Mar 2026 — SOU EXTENSION 1 FILED
- 27 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 30 Dec 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 04 Nov 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 04 Nov 2025 — PUBLISHED FOR OPPOSITION
- 29 Oct 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Oct 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 01 Aug 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 01 Aug 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 01 Aug 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 28 Jul 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 28 Jul 2025 — NON-FINAL ACTION E-MAILED
- 28 Jul 2025 — NON-FINAL ACTION WRITTEN